H-89

• UNSPSC Description:

  H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.

• Target Antigen:

  Autophagy; PKA

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/H-89.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=S(C1=CC=CC2=C1C=CN=C2)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O

• Molecular Weight:

  446.36

• References & Citations:

  [1]Chijiwa T, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267-72.|[2]Blazev R, et al. Effects of the PKA inhibitor H-89 on excitation-contraction coupling in skinned and intact skeletal muscle fibres. J Muscle Res Cell Motil. 2001;22(3):277-86.|[3]Hosseini-Zare MS, et al. Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice. Eur J Pharmacol. 2011 Nov 30;670(2-3):464-70.Acta Biochim Biophys Sin (Shanghai). 2023 Nov 15;55(12):1855-1863.|Adv Sci (Weinh). 2024 Jul 1:e2403640.|Am J Physiol Cell Physiol. 2024 Apr 22.|Anim Nutr. 2022.|Aquac Rep. 2024 Jun, 36, 102110.|Aquac Res. 2020;00:1-10.|Arch Biochem Biophys. 2020 Jul 15;687:108375.|Biol Pharm Bull. 2024;47(6):1113-1118.|Biomaterials. 2022: 121902|Biomed Pharmacother. 2022 Feb 24;148:112728.|BMC Biol. 2024 May 3;22(1):104.|BMC Genomics. 2024 Apr 3;25(1):337.|BMC Pharmacol Toxicol. 2023 Nov 20;24(1):63.|Bone. 2020 Jun;135:115326.|Brain Behav Immun. 2023 Nov 19:115:667-679.|Brain Behav Immun. 2024 Mar 29:119:36-50.|Cancer Cell Int. 2019 Sep 23;19:241.|Cell Commun Signal. 2021 Oct 11;19(1):103.|Cell Commun Signal. 2024 Jul 25;22(1):375.|Cell Death Dis. 2024 Sep 30;15(9):699.|Cell Metab. 2021 Mar 2;33(3):565-580.e7.|Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2.|Cell Mol Immunol. 2023 Jan 5.|Cell Rep. 2021 Sep 21;36(12):109726.|Cell Rep. 2022 Oct 18;41(3):111498.|Cells. 2023 Apr 6, 12(7), 1098.|Chem Biol Interact. 2024 Sep 2:111224.|Clin Transl Med. 2021 Jan 1.|CNS Neurosci Ther. 2024 May;30(5):e14742.|Ecotoxicol Environ Saf. 2021 Feb 25;214:112005.|Endocrinology. 2023 Mar 17;bqad042.|Evid-Based Compl Alt. Dec 12.|Fitoterapia. 2022 Oct 15;105336.|Free Radic Biol Med. 2024 May 31:222:72-84.|Front Oncol. 2021 Oct 6;11:738300.|Front Physiol. 05 January 2022.|Front Physiol. 2021 Oct 28;12:770430.|Genes Dis. 2020 Nov 21;8(6):867-881.|Heart Surg Forum. 2024 Mar 17.|Heliyon. 2024 Sep 19;10(19):e37958.|Infect Immun. 2018 Dec 19;87(1). pii: e00508-1|Int J Biol Sci. 2024 Aug 19;20(11):4476-4495.|Int J Mol Sci. 2018 Oct 7;19(10). pii: E3053. |Int J Mol Sci. 2022, 23(20), 12595.|Int J Mol Sci. 2023 Jan 16;24(2):1771.|Int J Mol Sci. 2023, 24(1), 320.|iScience. 2021, 102820.|J Agric Food Chem. 2023 Oct 23.|J Biol Chem. 2021 Apr 8;100644.|J Bone Miner Metab. 2021 Apr 8.|J Cell Mol Med. 2024 Apr;28(8):e18303.|J Exp Clin Cancer Res. 2021 Apr 8;40(1):122.|J Exp Clin Cancer Res. 2024 Apr 4;43(1):105.|J Int Med Res. 2021 Mar;49(3):300060521999527.|J Integr Agric. 2023 Feb 24.|J Mater Sci Technol. 2023 Jun 30.|J Neurophysiol. 2023 Dec 5.|J Neurosci. 2016 Oct 12;36(41):10560-10573.|J Orthop Surg Res. 2023 Nov 8;18(1):849.|J Periodontol. 2019 Sep;90(9):1002-1013.|Korean J Pain. 2023 Jul 1;36(3):335-346.|Microbiol Res. 2024 May 24:285:127779.|Mol Brain. 2021 Jul 19;14(1):116.|Mol Cell. 2023 Feb 22;S1097-2765(23)00102-8.|Mol Neurobiol. 2024 Jun 10.|Mol Reprod Dev. 2022 Apr 26.|Nat Commun. 2022 Nov 4;13(1):6648.|Neuro Oncol. 2024 Jan 5;26(1):137-152.|Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528.|NPJ Biofilms Microbiomes. 2023 Feb 8;9(1):8.|Nutr Diabetes. 2024 Jul 23;14(1):56.|Nutrients. 2020 Jan 26;12(2):329.|Proteome Sci. 2023 Oct 11;21(1):16.|Psychoneuroendocrinology. 2020 Jul;117:104680.|Res Sq. 2024 Jul 15.|Res Sq. 2024 May 23.|Research Square Preprint. 2020 Oct.|Research Square Preprint. 2023 Sep 13.|Royal Society of Chemistry. 2020, 11, 1132-1139.|Sci Signal. 2020 Nov 24;13(659):eaax0273.|Signal Transduct Target Ther. 2023 Aug 9;8(1):290.|Small Methods. 2024 Oct 17:e2401144.|Stem Cell Res Ther. 2020 Jan 3;11(1):2.|Theranostics. 2021 Mar 24;11(12):5650-5674.|Toxicol Lett. 2022 Feb 7;359:84-95.|Acta Pharm Sin B. 2023 Dec 16.|Adv Sci (Weinh). 2021 Oct 31;e2100808.|Aging (Albany NY). 2018 Jul 24;10(7):1722-1744. |Aging (Albany NY). 2020 Jun 9;12(11):10951-10968.|Aging Cell. 2018 Jun;17(3):e12754. |Biochem Biophys Res Commun. 2024 Feb 15, 149689.|Biol Trace Elem Res. 2020 Sep 14. |bioRxiv. 2024 Feb 8.|bioRxiv. 2024 Oct 2:2024.09.30.615856.|bioRxiv. 2024 Oct 22:2024.10.18.619152.|Cell Commun Signal. 2022 Apr 12;20(1):52.|Elife. 2023 Jan 16;12:e81438.|Environ Health (Wash). 2024 Aug 16;2(11):776-785.|Exp Cell Res. 2021 Feb 15;399(2):112482.|Exp Ther Med. January 31, 2022.|FASEB J. 2020 Oct;34(10):13376-13395.|Front Pharmacol. 2018 Apr 12;9:362. |Harvard Medical School LINCS LIBRARY|IJMPNP. 2019,5(1): 8-15.|Int Immunopharmacol. 2024 Jan 12:128:111490.|Int J Biol Sci. 2023 Apr 2,19.|J Bone Miner Res. 2021 May 5.|J Cell Mol Med. 2020 Apr;24(8):4736-4747.|J Funct Foods. 2023 Dec, 111, 105902.|Life Sci. 2022 May 28;120676.|Nat Commun. 2023 May 31;14(1):3159.|Nat Metab. 2024 Apr;6(4):708-723.|PeerJ. October 25, 2022.|Peptides. 2022 Jun 2;170824.|Phytother Res. 2022 Nov 25.|Prog Neurobiol. 2021 Mar 22;102041.|Purinergic Signal. 2022 Jul 2.|Reprod Sci. 2022 Oct 7.|Research Square Preprint. 2024 Dec 04.|Sci Total Environ. 2022 Oct 10;842:156854.|Stem Cell Res Ther. 2020 May 19;11(1):182.|Theranostics. 2021 Jan 1;11(6):2612-2633.|Vet Microbiol. 2021, 109061.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  127243-85-0